Welcome to our dedicated page for Cabbacis news (Ticker: CABI), a resource for investors and traders seeking the latest updates and insights on Cabbacis stock.
Cabbacis Inc (OTCQB: CABI) is a U.S. federally licensed tobacco-product manufacturer focused on harm-reduction products developed under its iBlend™ brand. The Cabbacis news feed on Stock Titan brings together company press releases and market updates that explain how the business is progressing with reduced-nicotine cigarettes and vaporizer pods that are predominately tobacco and include hemp.
In its news, Cabbacis highlights developments such as clinical trial results for its patented iBlend™ reduced-nicotine cigarettes, which the company reports were highly rated for satisfaction and significantly reduced cravings for usual brand cigarettes. Updates also cover new patents for vaporizer pods that blend reconstituted tobacco and hemp, expansion of its global intellectual property portfolio, and descriptions of how these patents apply across major tobacco markets.
Investors following CABI news can also read about capital markets milestones, including qualification of Regulation A (Tier 2) offerings, use of proceeds for product development and FDA Premarket Tobacco Product Applications, and the company’s DTC eligibility and OTCQB trading status. Additional releases describe participation in investor conferences, engagement of investor relations advisors, and commentary from management on the commercialization pathway for iBlend™ products.
This page aggregates these announcements so readers can review how Cabbacis presents its harm-reduction strategy, regulatory plans, patent activity and financing efforts over time. For those tracking the evolution of reduced-nicotine tobacco and hemp-based products, the CABI news stream offers direct access to the company’s own descriptions of its progress and objectives.
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco manufacturer, has filed its Annual Report for fiscal year 2024. The company, focused on developing harm-reduction products under the iBlend™ brand, reported increased losses with:
- Net loss from operations of $956,464 in 2024 (vs $380,174 in 2023)
- Total net loss of $915,886 in 2024 (vs $379,068 in 2023)
- Negative EPS of $0.15 (vs -$0.07 in 2023)
As a development-stage company, CABI generated no revenue in 2024. The company reports significant progress in product development, including their ongoing clinical trial of iBlend™ reduced-nicotine cigarettes, which is over 50% complete.
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco product manufacturer and plant biotech company, has received DTC Eligibility approval from the Depository Trust Company. This development follows the company's previous listing approval on the OTCQB under the symbol 'CABI'.
DTC, a subsidiary of the Depository Trust and Clearing (DTCC), manages electronic clearing and settlement of publicly traded companies' shares. The DTC Eligibility status enables electronic clearing and settlement of Cabbacis shares, expediting stock and cash receipt processes while simplifying trading and share transfers between brokerage companies.
Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco product manufacturer and plant biotech company, has received approval for listing its common stock on the OTCQB Venture Market. The OTCQB, operated by OTC Markets Group, serves entrepreneurial and development stage companies among its 12,000+ securities. The company expects this listing to enhance shareholder liquidity, transparency, and expand its investor reach.